MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy

By sjmartinez • February 27, 2023

He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, Olson P, Latven L, Yan X, Shazer R, Leal TA. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol. 2023 Feb 24:S1556-0864(23)00158-2. doi: 10.1016/j.jtho.2023.02.016. Epub ahead of print. PMID: 36842467.

Tags: antitumor activity, Hematology/Oncology, nivolumab, NSCLC, Publications, sitravatinib, Tyrosine kinase inhibitor

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review

Smith CE, Sammons SL, Minami CA, Sedrak MS, Magnuson A, O'Connor T, Hshieh TT, Smith S, Ruderman K, Bak K, Lin NU, Freedman RA. Systemic[...]

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers

Shachar EK, Silverstein J, Gornbein J, Salani R, Karlan BY, Chase DM. Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related[...]

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]